The heart: Pathophysiology and clinical implications of cirrhotic cardiomyopathy

Journal of the Chinese Medical Association

Volumn 75, Issue 12, 2012, Pages 619-623

  Yang, Ying Ying ^a,b   Lin, Han Chieh ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cirrhotic cardiomyopathy; Hyperdynamic circulation; Portal hypertension

Indexed keywords

BETA ADRENERGIC RECEPTOR; DOBUTAMINE; ENDOCANNABINOID; ENDOTOXIN; HUMORAL ANTIBODY; NITRIC OXIDE; SODIUM;

ARTICLE; CIRCULATION; CIRRHOTIC CARDIOMYOPATHY; DIAGNOSTIC PROCEDURE; DIASTOLIC DYSFUNCTION; FLUID RETENTION; HEART DISEASE; HEART FAILURE; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MORBIDITY; PATHOPHYSIOLOGY; POSTOPERATIVE PERIOD; PREVALENCE; QRS COMPLEX; SARCOPLASMIC RETICULUM; SODIUM RETENTION; SURVIVAL RATE; VASODILATATION;

EID: 84870935305     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2012.08.015     Document Type: Review

References (49)

1. Kowalski H.J., Abelmann W.H. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953, 32:1025-1033.
2. Lee S.S. Cardiac abnormalities in liver cirrhosis. West J Med 1989, 151:530-535.
3. Ma Z., Lee S.S. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996, 24:451-459.
4. Møller S., Henriksen J.H. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002, 87:9-15.
5. Baik S.K., Lee S.S. Cirrhotic cardiomyopathy: causes and consequences. J Gastroenterol Hepatol 2004, 19:S185-S190.
6. Gaskari S.A., Honar H., Lee S.S. Therapy insight: cirrhotic cardiomyopathy. Nat Clin Pract Gastroenterol Hepatol 2006, 3:329-337.
7. Gould L., Shariff M., Zahir M., Di Lieto M. Cardiac hemodynamics in alcoholic patients with chronic liver disease and a presystolic gallop. J Clin Invest 1969, 48:860-868.
8. Ratti L., Redaelli E., Guidi C., Rivera R., Wong F., Pozzi M. Diastolic dysfunction in liver cirrhosis. Gastroenterol Hepatol 2005, 28:649-655. [article in Spanish].
9. Donovan C.L., Marcovitz P.A., Punch J.D., Bach D.S., Brown K.A., Lucey M.R., et al. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation 1996, 61:1180-1188.
10. Myers R.P., Lee S.S. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 2000, 4(Suppl 1):S44-S52.
11. Therapondos G., Flapan A.D., Plevris J.N., Hayes P.C. Cardiac morbidity and mortality related to orthotopic liver transplantation. Liver Transpl 2004, 10:1441-1453.
12. Merli M., Valeriano V., Funaro S., Attili A.F., Masini A., Efrati C., et al. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol 2002, 97:142-148.
13. Ginès P., Uriz J., Calahorra B., Garcia-Tsao G., Kamath P.S., Del Arbol L.R., et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002, 123:1839-1847.
14. Cazzaniga M., Salerno F., Pagnozzi G., Dionigi E., Visentin S., Cirello I., et al. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut 2007, 56:869-875.
15. Lee S.S., Liu H. Cardiovascular determinants of survival in cirrhosis. Gut 2007, 56:746-748.
16. Ruiz-del-Arbol L., Urman J., Fernández J., González M., Navasa M., Monescillo A., et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003, 38:1210-1218.
17. Ruiz-del-Arbol L., Monescillo A., Arocena C., Valer P., Ginès P., Moreira V., et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005, 42:439-447.
18. Prabhu S.D. Cytokine-induced modulation of cardiac function. Circ Res 2004, 95:1140-1153.
19. Bernardi M., Calandra S., Colantoni A., Trevisani F., Raimondo M.L., Sica G., et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998, 27:28-34.
20. Henriksen J.H., Fuglsang S., Bendtsen F., Christensen E., Møller S. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol 2002, 36:513-520.
21. Birnbaumer L. Expansion of signal transduction by G proteins. The second 15 years or so: from 3 to 16 alpha subunits plus betagamma dimers. Biochim Biophys Acta 2007, 1768:772-793.
22. Jaue D.N., Ma Z., Lee S.S. Cardiac muscarinic receptor function in rats with cirrhotic cardiomyopathy. Hepatology 1997, 25:1361-1365.
23. Sucharov C.C. Beta-adrenergic pathways in human heart failure. Expert Rev Cardiovasc Ther 2007, 5:119-124.
24. Marian A.J. Beta-adrenergic receptors signaling and heart failure in mice, rabbits and humans. J Mol Cell Cardiol 2006, 41:11-13.
25. Lee S.S., Marty J., Mantz J., Samain E., Braillon A., Lebrec D. Desensitization of myocardial beta-adrenergic receptors in cirrhotic rats. Hepatology 1990, 12:481-485.
26. Ma Z., Meddings J.B., Lee S.S. Membrane physical properties determine cardiac beta-adrenergic receptor function in cirrhotic rats. Am J Physiol 1994, 267:G87-G93.
27. Ma Z., Miyamoto A., Lee S.S. Role of altered beta-adrenoceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. Gastroenterology 1996, 110:1191-1198.
28. Ma Z., Zhang Y., Huet P.M., Lee S.S. Differential effects of jaundice and cirrhosis on beta-adrenoceptor signaling in three rat models of cirrhotic cardiomyopathy. J Hepatol 1999, 30:485-491.
29. Ma Z., Lee S.S., Meddings J.B. Effects of altered cardiac membrane fluidity on beta-adrenergic receptor signalling in rats with cirrhotic cardiomyopathy. J Hepatol 1997, 26:904-912.
30. Ma Z., Meddings J.B., Lee S.S. Cardiac plasma membrane physical properties and beta-adrenergic receptor function are unaltered in portal-hypertensive rats. Hepatology 1995, 22:188-193.
31. Bátkai S., Járai Z., Wagner J.A., Goparaju S.K., Varga K., Liu J., et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001, 7:827-832.
32. Gaskari S.A., Liu H., Moezi L., Li Y., Baik S.K., Lee S.S. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol 2005, 146:315-323.
33. Moezi L., Gaskari S.A., Liu H., Baik S.K., Dehpour A.R., Lee S.S. Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors. Br J Pharmacol 2006, 149:898-908.
34. Pacher P., Bátkai S., Kunos G. Cirrhotic cardiomyopathy: an endocannabinoid connection?. Br J Pharmacol 2005, 146:313-314.
35. Lin H.C., Yang Y.Y., Tsai T.H., Huang C.M., Huang Y.T., Lee F.Y., et al. The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension. J Hepatol 2011, 45:1145-1153.
36. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002, 91:988-998.
37. Ward C.A., Liu H., Lee S.S. Altered cellular calcium regulatory systems in a rat model of cirrhotic cardiomyopathy. Gastroenterology 2001, 121:1209-1218.
38. Henderson J.M., Mackay G.J., Hooks M., Chezmar J.L., Galloway J.R., Dodson T.F., et al. High cardiac output of advanced liver disease persists after orthotopic liver transplantation. Hepatology 1992, 15:258-262.
39. Navasa M., Feu F., García-Pagán J.C., Jiménez W., Llach J., Rimola A., et al. Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology 1993, 17:355-360.
40. Piscaglia F., Zironi G., Gaiani S., Mazziotti A., Cavallari A., Gramantieri L., et al. Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study. Hepatology 1999, 30:58-64.
41. Ripoll C., Catalina M.V., Yotti R., Olmedilla L., Pérez-Peña J., Lo Iacono O., et al. Cardiac dysfunction during liver transplantation: incidence and preoperative predictors. Transplantation 2008, 85:1766-1772.
42. Gadano A., Hadengue A., Widmann J.J., Vachiery F., Moreau R., Yang S., et al. Hemodynamics after orthotopic liver transplantation: study of associated factors and long-term effects. Hepatology 1995, 22:458-465.
43. Torregrosa M., Aguadé S., Dos L., Segura R., Gónzalez A., Evangelista A., et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005, 42:68-74.
44. Mohamed R., Forsey P.R., Dvies M.K., Neuberger J.M. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology 1996, 23:1128-1134.
45. Mandell M.S., Tsou M.Y. Cardiovascular dysfunction in patients with end-stage liver disease. J Chin Med Assoc 2008, 71:331-335.
46. Carey E.J., Gautam M., Ingall T., Douglas D.D. The effect of liver transplantation on autonomic dysfunction in patients with end-stage liver disease. Liver Transpl 2008, 14:235-239.
47. García González M., Hernandez-Madrid A., Lopez-Sanromán A., Candela A., Nuño J., Barcena R. Reversal of QT interval electrocardiographic alterations in cirrhotic patients undergoing liver transplantation. Transplant Proc 1999, 31:2366-2367.
48. Adigun A.Q., Pinto A.G., Flockhart D.A., Gorski J.C., Li L., Hall S.D., et al. Effect of cirrhosis and liver transplantation on the gender difference in QT interval. Am J Cardiol 2005, 95:691-694.
49. Møller S., Henriksen J.H. Cirrhotic cardiomyopathy. J Hepatol 2010, 53:179-190.